Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: a randomized-controlled trial
Angioedema due to acquired C1-inhibitor deficiency is a very rare but serious disease, with an estimated prevalence of 1 per 500,000 persons. There are no approved therapies to treat or prevent angioedema swellings in patients with this condition. Deucrictibant is a specific, orally bioavailable, competitive antagonist of the bradykinin B2 receptor currently under investigation for hereditary angioedema.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Remy S. Petersen, Laur é M. Fijen, Johannes P. Kelder, Danny M. Cohn Source Type: research
More News: Allergy | Allergy & Immunology